Institutional members access full text with Ovid®

Share this article on:

Zinc-α2-glycoprotein as a marker of fat catabolism in humans

Cabassi, Aderville; Tedeschi, Stefano

Current Opinion in Clinical Nutrition & Metabolic Care: May 2013 - Volume 16 - Issue 3 - p 267–271
doi: 10.1097/MCO.0b013e32835f816c
TRANSLATIONAL RESEARCH IN WASTING DISEASES: Edited by Vickie E. Baracos, Didier Attaix and Claude Pichard

Purpose of review: Cachexia development is a feature of cancer as well as other chronic diseases. Fat mass loss appears of greatest importance in cachexia, as it is related to poorer survival. Zinc-α2-glycoprotein (ZAG), firstly isolated in human plasma 50 years ago, has emerged as a novel adipokine, which plays an important role in mobilization and utilization of lipids. This review will focus on recent evidences of ZAG as a fat catabolic marker in cancer and other diseases complicated by cachexia.

Recent findings: ZAG is a lipolytic factor produced by certain cachexia-inducing tumuors and by adipose tissue. It increases lipolysis in white adipose tissue through cyclic-AMP pathway and stimulates uncoupling protein-1 in brown adipose tissue leading to heat generation. In cancer cachexia, ZAG release from white adipocytes is elevated and closely related to body weight loss. In cardiac cachexia, ZAG and circulating free fatty acids are closely related, suggesting a causative role in fat catabolism.

Summary: ZAG may play an important role, probably as an autocrine/paracrine modulator of adipose mass in cachexia. A better comprehension of ZAG involvement in fat wasting mechanisms will be useful in the development of new therapeutic agents.

Cardiorenal Research Unit, Department of Clinical and Experimental Medicine, University of Parma, Parma, Italy

Correspondence to Aderville Cabassi, MD, Cardiorenal Research Unit, Department of Clinical and Experimental Medicine, University of Parma, Via Gramsci 14, 43126 Parma, Italy. Tel: +390 521 702 898; fax: +390 521 033 185; e-mail: aderville.cabassi@unipr.it

© 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins